Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Harrington

Showing results (131-140 of 197) with videos related to

Pageof 20
Sort By:
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
BMJ Open|March 19, 2020
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocolAnthony Kong, James Good, Amanda Kirkham, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Cancer Immunology Research|October 18, 2017
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor RecurrenceTim Kottke, Laura Evgin, Kevin G Shim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Iscience|September 12, 2024
Cancer cell - Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinomaGiovanni Giangreco, Antonio Rullan, Yutaka Naito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaNeil N Senzer, Howard L Kaufman, Thomas Amatruda, et al.
Oral Oncology|January 25, 2020
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N studyViktor Grünwald, Diana Chirovsky, Winson Y Cheung, et al.
Head & Neck|August 28, 2021
What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?Mark Edmond, Pablo Nenclares, Kevin Harrington, et al.
Pageof 20

Showing results (131-140 of 197) with videos related to

Sort By:
Pageof 20
Nature Medicine|November 19, 2013
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrenceTimothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, et al.
BMJ Open|March 19, 2020
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocolAnthony Kong, James Good, Amanda Kirkham, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 30, 2014
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory AgentsShane Zaidi, Miran Blanchard, Kevin Shim, et al.
Cancer Immunology Research|October 18, 2017
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor RecurrenceTim Kottke, Laura Evgin, Kevin G Shim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancerTimothy Kottke, Rosa M Diaz, Karen Kaluza, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 26, 2014
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical siteVanesa Alonso-Camino, Karishma Rajani, Timothy Kottke, et al.
Iscience|September 12, 2024
Cancer cell - Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinomaGiovanni Giangreco, Antonio Rullan, Yutaka Naito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaNeil N Senzer, Howard L Kaufman, Thomas Amatruda, et al.
Oral Oncology|January 25, 2020
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N studyViktor Grünwald, Diana Chirovsky, Winson Y Cheung, et al.
Head & Neck|August 28, 2021
What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?Mark Edmond, Pablo Nenclares, Kevin Harrington, et al.
Pageof 20